BioActive B-Complex 60 Capsules

RN Labs BioActive B-Complex is a pure, balanced, and hypoallergenic source of metabolically active forms of B complex vitamins, providing a highly versatile foundation to further supplementation (including the methylated vitamin forms).

The vitamins in BioActive B-Complex have been demonstrated to support a range of metabolic processes, including energy production, detoxification processes, neurological health, stress response, and hormone balance.

The bioactive, yet unmethylated, forms are used to support optimal activity, without causing over-stimulation, particularly in sensitive patients.

Hydroxocobalamin Vs. Cyanocobalamin
Hydroxocobalamin and cyanocobalamin were compared for their efficacy in lowering elevated blood methylmalonic acid and urine homocysteine in cobalamin-deficient patients.

Each patient did experience a significant decrease in urine methylmalonic acid excretion while receiving cyanocobalamin, but levels remained at least 10 times normal. Cyanocobalamin treatment resulted in a decrease of plasma homocysteine to near normal in one patient but had no effect on plasma homocysteine in another patient.

Each patient was then switched to hydroxocobalamin where they experienced a decrease in methylmalonic acid levels to the limits of detection. Plasma homocysteine values while taking hydroxocobalamin also remained significantly decreased at < 5 nmol/ml in all patients.

In one patient, who continued to receive cyanocobalamin therapy for more than 1 year, growth rates (height, weight, and head circumference) were very poor. After the initiation of hydroxocobalamin, growth parameters normalized with growth rates returning above normal.

The authors concluded that cyanocobalamin treatment is inadequate in the treatment of patients with cobalamin C disease, and appropriate management should include only the hydroxocobalamin form of cobalamin.

Andersson, HC & Shapira, E 1998, ‘Biochemical and clinical response to hydroxocobalamin versus cyanocobalamin treatment in patients with methylmalonic acidemia and homocystinuria (cblC)’, The Journal of Pediatrics, vol. 132, pp. 121-4.